Global Neuro-Oncology Diagnostics Market Research Report – Segmented By Test Type (Imaging Test, Biopsy, Lumber Puncture, Molecular Testing, Electroencephalography (EEG), Platform/Services and Others); By Cancer Type (Acoustic Neuroma, Astrocytomas, Glioblastoma Multiforme, Meningiomas, Oligodendroglioma, and Others); By Age Group (0-15, 15-39, 40-65, 65 and above); By End User (Hospitals, Specialty Clinics, Diagnostic Centers & Research Institutes, Ambulatory Surgical Centers, and Others); and Region- Size, Share, Growth Analysis | Forecast (2024 – 2030)

Chapter 1. Neuro-Oncology Diagnostics Market  – Scope & Methodology
1.1    Market Segmentation
1.2    Scope, Assumptions & Limitations
1.3    Research Methodology
1.4    Primary Sources
1.5    Secondary Sources
Chapter 2. Neuro-Oncology Diagnostics Market – Executive Summary
2.1    Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2    Key Trends & Insights
               2.2.1    Demand Side
               2.2.2    Supply Side
2.3    Attractive Investment Propositions
2.4    COVID-19 Impact Analysis 
Chapter 3. Neuro-Oncology Diagnostics Market  – Competition Scenario
3.1    Market Share Analysis & Company Benchmarking
3.2    Competitive Strategy & Development Scenario
3.3    Competitive Pricing Analysis
3.4    Supplier-Distributor Analysis 
Chapter 4. Neuro-Oncology Diagnostics Market  Entry Scenario
4.1    Regulatory Scenario
4.2    Case Studies – Key Start-ups
4.3    Customer Analysis
4.4    PESTLE Analysis
4.5    Porters Five Force Model
               4.5.1    Bargaining Power of Suppliers
               4.5.2    Bargaining Powers of Customers
               4.5.3    Threat of New Entrants
               4.5.4    Rivalry among Existing Players
               4.5.5    Threat of Substitutes 
Chapter 5. Neuro-Oncology Diagnostics Market  – Landscape
5.1    Value Chain Analysis – Key Stakeholders Impact Analysis
5.2    Market Drivers
5.3    Market Restraints/Challenges
5.4    Market Opportunities 
Chapter 6. Neuro-Oncology Diagnostics Market  – By Test Type
6.1    Introduction/Key Findings   
6.2    Imaging Tests
6.3    Biopsy
6.4    Lumbar Puncture
6.5    Molecular Testing
6.6    Electroencephalography (EEG)
6.7    Platform and Services
6.8    Others
6.9    Y-O-Y Growth trend Analysis By Test Type
6.10    Absolute $ Opportunity Analysis By Test Type, 2023-2030
Chapter 7. Neuro-Oncology Diagnostics Market  – By Cancer Type
7.1    Introduction/Key Findings   
7.2    Acoustic Neuroma
7.3    Astrocytomas
7.4    Glioblastoma Multiforme
7.5    Meningiomas                             
7.6    Oligodendroglioma
7.7    Others
7.8    Y-O-Y Growth  trend Analysis By Cancer Type
7.9    Absolute $ Opportunity Analysis By Cancer Type, 2024-2030
Chapter 8. Neuro-Oncology Diagnostics Market  – By Age Group
8.1    Introduction/Key Findings   
8.2    0-15
8.3    15-39
8.4    40-65
8.5    65 and above
8.6    Y-O-Y Growth trend Analysis By Age Group
8.7    Absolute $ Opportunity Analysis By Age Group, 2023-2030
Chapter 9. Neuro-Oncology Diagnostics Market  – By End-User
9.1    Introduction/Key Findings   
9.2    Hospitals
9.3    Specialty clinics
9.4    Diagnostic centers and research institutes
9.5    Ambulatory surgical centers
9.6    Others 
9.7    Y-O-Y Growth trend Analysis End-User
9.8    Absolute $ Opportunity Analysis End-User, 2024-2030
Chapter 10. Neuro-Oncology Diagnostics Market , By Geography – Market Size, Forecast, Trends & Insights
10.1    North America
                10.1.1    By Country
                              10.1.1.1    U.S.A.
                              10.1.1.2    Canada
                              10.1.1.3    Mexico
               10.1.2    By Test Type
                              10.1.2.1    By Cancer Type
               10.1.3    By Age Group
               10.1.4    Countries & Segments - Market Attractiveness Analysis
10.2    Europe
               10.2.1    By Country
                              10.2.1.1    U.K
                              10.2.1.2    Germany
                              10.2.1.3    France
                              10.2.1.4    Italy
                              10.2.1.5    Spain
                              10.2.1.6    Rest of Europe
               10.2.2    By Test Type
               10.2.3    By Cancer Type
               10.2.4    By Age Group
               10.2.5    By End-User
               10.2.6    Countries & Segments - Market Attractiveness Analysis
10.3    Asia Pacific
               10.3.1    By Country
                              10.3.1.1    China
                              10.3.1.2    Japan
                              10.3.1.3    South Korea
                              10.3.1.4    India      
                              10.3.1.5    Australia & New Zealand
                              10.3.1.6    Rest of Asia-Pacific
               10.3.2    By Test Type
               10.3.3    By Cancer Type
               10.3.4    By Age Group
               10.3.5    By End-User
               10.3.6    Countries & Segments - Market Attractiveness Analysis
10.4    South America
               10.4.1    By Country
                              10.4.1.1    Brazil
                              10.4.1.2    Argentina
                              10.4.1.3    Colombia
                              10.4.1.4    Chile
                              10.4.1.5    Rest of South America
               10.4.2    By Test Type
               10.4.3    By Cancer Type
               10.4.4    By Age Group
               10.4.5    By End-User
               10.4.6    Countries & Segments - Market Attractiveness Analysis
10.5    Middle East & Africa
               10.5.1    By Country
                              10.5.1.1    United Arab Emirates (UAE)
                              10.5.1.2    Saudi Arabia
                              10.5.1.3    Qatar
                              10.5.1.4    Israel
                              10.5.1.5    South Africa
                              10.5.1.6    Nigeria
                              10.5.1.7    Kenya
                              10.5.1.8    Egypt
                              10.5.1.9    Rest of MEA
               10.5.2    By Test Type
               10.5.3    By Cancer Type
               10.5.4    By Age Group
               10.5.5    By End-User
               10.5.6    Countries & Segments - Market Attractiveness Analysis
 Chapter 11. Neuro-Oncology Diagnostics Market  – Company Profiles – (Overview, Product Portfolio, Financials, Strategies & Developments)
11.1    NIHON KOHDEN CORPORATION.
11.2    FUJIFILM Holdings Corporation
11.3    GE HealthCare
11.4    Koninklijke Philips N.V.
11.5    BD
11.6    Siemens Healthcare GmbH
11.7    Others


 

Download Sample

The field with (*) is required.

Choose License Type

$

2500

$

4250

$

5250

$

6900

Frequently Asked Questions

Global Neuro-Oncology Diagnostics Market was valued at USD 1.80 Billion and is projected to reach a market size of USD 3.21 Billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 8.6%.

The worldwide global neuro-oncology diagnostics market growth is estimated to grow by around 8.6% from 2023 to 2030.

The Global NeuroOncology Diagnostics Market is segmented by Test Type, by Cancer Type, by Age Group, and by End User.

 The market is expected to see growth through rising awareness of early diagnosis of brain cancer, advancements in technologies like improved imaging techniques, along innovation in drug delivery to brain cancer increasing the size of the market.

The COVID-19 pandemic disrupted the supply chain of the diagnostic market reducing the overall market size in 2020. However, the market is increasing as people have to get diagnosed after the lockdown scenario.